Registration, quality assurance and the shape of a medicines contract
A medicines tender is decided on quality assurance before it is decided on price. Bidders must show that the product is authorised or registered for use in the destination market, that it is manufactured at a site holding current good manufacturing practice certification, and -- for many donor-funded and essential medicines programs -- that the product or its manufacturer appears on a recognised prequalification list. These are documentary conditions of admissibility assessed against the specific product and manufacturing site offered, and a change of site after award is a contractual event, not an administrative one.
Products are specified by international non-proprietary name, strength and dosage form so that generics compete openly, with pharmacopoeial standards cited for quality. Delivery conditions carry as much weight as the product: a minimum proportion of shelf life remaining on arrival, batch certificates of analysis, tamper-evident and correctly labelled packaging in the required language, and unbroken cold chain with temperature monitoring for products that need it. A consignment that arrives with too little shelf life left is routinely rejected at the buyer's cost to the supplier.
The commercial structure is usually a framework at agreed unit prices with call-offs against forecast rather than firm volume, because demand depends on disease patterns and program funding. That places emphasis on lead times, on the supplier's obligation to hold or replenish stock, and on what happens in a shortage -- allocation, substitution and notification terms are increasingly explicit. Recall capability is tested rather than assumed: buyers ask how quickly a batch can be traced and withdrawn from every facility it reached.
This section describes how this category is bought generally, across the public buyers that publish it. The figures elsewhere on this page are measured for this market alone.
Who buys pharmaceuticals in Iceland?
GlobalGov holds 49 pharmaceuticals records from 6 distinct buying organizations in Iceland. The most frequent publishers are International buyer (17 records); Ríkiskaup (The Central Public Procurement) (9 records); Ríkiskaup (6 records); International buyer (4 records); International buyer (3 records); Ríkiskaup (3 records). Between them the 6 largest account for 86% of everything published, so buying here is concentrated in a few authorities.
| Buying organization | Records | Share |
|---|---|---|
| International buyer | 17 | 35% |
| Ríkiskaup (The Central Public Procurement) | 9 | 18% |
| Ríkiskaup | 6 | 12% |
| International buyer | 4 | 8.2% |
| International buyer | 3 | 6.1% |
| Ríkiskaup | 3 | 6.1% |
What are pharmaceuticals contracts worth in Iceland?
15 of the 49 records publish a contract value. The median is $2.9M and the largest single published value is $100.7M. By size, 4 between $100k and $1M, 9 between $1M and $10M, 2 above $10M. The remaining 34 publish no value at all, so every figure here describes the priced subset only, and values are as stated by the buyer rather than as finally awarded.
| Contract size | Records | Share of priced |
|---|---|---|
| under $100k | 0 | 0.0% |
| between $100k and $1M | 4 | 27% |
| between $1M and $10M | 9 | 60% |
| above $10M | 2 | 13% |
How long do bidders get to respond to pharmaceuticals tenders in Iceland?
Across the 13 Iceland pharmaceuticals notices that publish both a publication date and a closing date, the median response window is 32 days. A quarter of them allowed 26 days or fewer and a quarter stayed open for more than 36. Short turnarounds are the exception rather than the rule here: only 1 (7.7%) closed within a fortnight of being published.
How often are pharmaceuticals tenders published in Iceland?
Iceland published 22 notices in this category in the last twelve months. Over the last three years there were 28, spread across 22 separate months of activity since 18 February 2017. September is historically the busiest month. The most recent was published 16 November 2026.
How does Iceland compare with other pharmaceuticals markets?
Among the 45 countries where GlobalGov holds a comparable pharmaceuticals market, Iceland ranks 43rd by number of records. The largest is Poland (9,417 records against 49 here). Within Iceland itself, pharmaceuticals is the 8th largest of the 14 procurement categories tracked here.
Where do the Iceland pharmaceuticals records on this page come from?
These 49 records are collected from 1 official source: TED (49). GlobalGov is an independent aggregator and is not affiliated with any of them; each record links back to the notice on its issuing portal. The set is rebuilt nightly, and the counts on this page were taken on 2026-11-22.
Open Pharmaceuticals tenders in Iceland
No individual notice in this category currently has a public record page. The market figures above are computed over all 49 records GlobalGov holds for it.
Other procurement categories in Iceland
Pharmaceuticals procurement in other markets
Never Miss a Iceland Government Contract
Finding Iceland tenders usually means a local portal, a local registration and someone who reads the language. Get an alert you can read when a new pharmaceuticals opportunity is published there.
Start Free Trial